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Abstract: The search for an effective and non-toxic radioprotector is ongoing. We tested a novel, natural aminothiol-based 
radioprotector, GL2011, that was applied 30 min, 3 h or 6 h after the exposure of male albino Wistar rats to a 6.7 Gy mild 
dose of gamma radiation. The molecular signatures of radioprotection were investigated with Raman microspectroscopy 
of brainstem tissue samples. Morphological changes and activation of astrocytes and microglia were assessed by immu-
nohistochemistry. Global markers of neuroinflammation were followed by ELISA to monitor blood plasma levels of pro-
inflammatory (IL-6 and TNF-α) and anti-inflammatory (IL-10) cytokines. A thirty-day follow-up determined survival 
of unprotected animals 37.5%. A survival increase was observed after radioprotection (75%, irrespective of the time of 
application). Raman spectra revealed a slightly deleterious effect of radiation on nucleic acids in surviving animals that was 
mitigated with the radioprotector, as GL2011 preserved the morphology of both astrocytes and microglia, with reduced 
microglial infiltration. Cytokine assessment revealed an immunomodulatory effect of the novel radioprotector. The overall 
results point out the positive effects of a single dose of GL2011 applied at different times. The molecular and cellular changes 
in the brainstem indicate that the radioprotector applied after radiation conferred better protection, which underlines its 
translation to cure radiation accidents.




In whole-body exposure to X- or gamma radiation 
(e.g. during radiation accidents) it is of particular in-
terest to assess the damage to brain tissue and to deter-
mine efficient means of radioprotection. At the molec-
ular and cellular levels, irradiation triggers a cascade 
of direct and indirect effects, including activation of 
early response transcription factors, signal transduc-
tion messengers, alterations of biomacromolecules 
and cellular effects particularly with regard to neuro-
glia [1,2]. From a biological perspective, the precise 
mechanisms of neurotoxicity and neurodegeneration 
following ionizing radiation exposure remain poorly 
elucidated [3] and post-irradiation therapy remains 
underdeveloped [4].
Radioprotectors are substances designed to reduce 
mortality and the harmful effects of ionizing radia-
tion. With regards to the potential application of ion-
izing radiation in external beam radiation therapy and 
in cases of accidental exposure to radiation, screen-
ing for radioprotective compounds is of great impor-
tance. Nevertheless, there is only one agent that has 
been approved by the Food and Drug Administration 
(USA) for use in cancer radiation treatment, and that 
is amifostine, (2-[(3-aminopropyl)amino]ethanethiol 
dihydrogen phosphate). In vitro and in vivo studies 
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have revealed the basis of its action in free radical-
scavenging [5]. However, amifostine is effective only 
if administered immediately prior to irradiation, so 
its use is of limited value in a number of clinical in-
dications and it is unsuitable for cases of incidental 
irradiation [6]. Moreover, it was found that amifos-
tine produces side effects such as nausea, hypoten-
sion, vomiting, hypocalcemia and allergic reactions 
[7]. Thus, its application is limited, especially at the 
higher doses necessary to enable successful radiopro-
tection, particularly in accidental radiation cases [8,9].
Among ongoing studies on both natural and syn-
thetic radioprotective agents, aminothiols have shown 
some promising results [10-12]. Various mechanisms 
of action of these radioprotectors on cellular DNA 
have been proposed, such as free radical scavenging, 
induction of hypoxia, formation of mixed disulfides, 
and hydrogen and electron donation as mechanisms 
of free radical elimination leading to restoration of 
damaged cellular components [13,14]. This study is a 
continuation of a preclinical trial of the radioprotec-
tive effects of a newly synthesized, naturally occurring 
aminothiol compound, GL2011 [15,16] that acts as an 
antioxidant and immunostimulatory agent. Its non-
toxicity to albino Wistar rats was also confirmed. After 
intraperitoneal application in three identical doses 
(100 mg/kg b.w.) at three time points (30 min prior 
to irradiation, 3 h and 6 h after irradiation), GL2011 
significantly reduced the mortality of whole-body 
irradiated animals (87% survival compared to 30% 
survival of unprotected animals [15]). GL2011 was 
shown to have a significant effect on the regenera-
tion of intestinal epithelial microvilli [15] and bone 
marrow cells of irradiated animals 30 days after treat-
ment [16]. The GL2011 radioprotector has also been 
shown to induce enhanced expression of proteins and 
antioxidant enzymes, including vimentin, septin-5, 
voltage-dependent anion selective channel protein and 
superoxide dismutase 2 [15].
The main goal of the present study was to focus 
on brain tissue of irradiated animals and to examine 
molecular and cellular changes that occur with or 
without the application of the GL2011 radioprotector. 
Thus, an innovative approach using Raman microspec-
troscopy was used to reveal its molecular signatures, 
while neuroglia, microglia and astrocytes, as cellular 
biomarkers of neuroinflammation, were followed 
immunohistochemically. The brainstem was chosen 
since it is one of the most radiosensitive structures of 
the central nervous system [17] and because it is the 
central regulator of essential bodily states and func-
tions, including respiratory and cardiovascular rhythms 
and blood pressure [18]. The existence of a bidirection-
al communication between the brain and the peripheral 
immune system is established [19], and follow-up of 
the levels of cytokines in the periphery may help in 
monitoring the recovery of injured CNS [20]. Therefore 
the overall effect of the radioprotector on neuroinflam-
mation, as indicated by the levels of pro- and anti-in-
flammatory cytokines, was also followed. 
MATERIALS AND METHODS
Animals
Experiments were performed on two-month-old male 
albino Wistar rats, weighing about 200 g. Male rats 
were chosen in order to avoid possible variability due 
to the estrous cycle of females and to keep the number 
of animals to a minimum (in compliance with the 3 
Rs principle). The animals were kept under standard 
laboratory conditions (room temperature 21±1°C, hu-
midity 30%, and a 12-h light/dark cycle) with food 
and tap water provided ad libitum. The protocols for 
animal housing and maintenance were in accordance 
with the European Directive 2010/63/EU [21] and 
the national regulations on the protection of animals 
used for scientific purposes. Experiments and ethical 
evaluation of the project were approved by the Ethics 
Committee of the Faculty of Biology, University of 
Belgrade (approval number EK-BF-2016/08). 
Experimental design
Six experimental groups were formed. The control 
group (CTRL) received neither radiation nor the 
radioprotector. The irradiated group (Irr) consisted 
of irradiated animals only, while the radioprotector 
control group (GL) was treated with the radiopro-
tector GL2011 (100 mg/kg i.p.) only and received no 
radiation. The dosage of the radioprotector was estab-
lished in our previous study [15]. In order to assess 
the molecular and cellular markers of radioprotection 
by one administration of GL2011 at different times, 
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three additional experimental groups were formed as 
follows: (i) GL2011 was administered 30 min prior 
to irradiation exposure (GLIr-30); (ii) 180 min post-
irradiation (GLIr180); (iii) 360 min post-irradiation 
(GLIr360). The experimental timeline for studying 
the radioprotective potential of GL2011 is shown in 
Supplementary Fig. S1.
Treatment with gamma radiation
A 60-cobalt (60Co) gamma-ray source was used for 
irradiation. Non-anesthetized immobilized animals 
were positioned in individual cages made of wire 
and arranged in a circle around the source (6 rats per 
session). The distance from the source was 25 cm, 
as per [22], where a similar setup and source were 
used. Body irradiation was performed with rats placed 
sideways to the source. The animals received 6.7 Gy 
radiation at a dose rate (0.41 Gy/min), which, based 
on literature data, corresponds to a LD50/30 dose [22-
24]. In the middle of a course of radiation treatment, 
the cages with rats were sideways rotated by 180° to 
provide uniform, whole-body irradiation. The sur-
viving animals were euthanized on day 30 and their 
tissue was used for further analysis. Animals that did 
not survive the 30 days were not included in further 
analyses. 
Survival analysis
The survival of animals was monitored throughout 
the experiment (30 days) in animals prepared for im-
munohistochemistry and enzyme-linked immunosor-
bent assay (ELISA). Each of the experimental groups 
comprised 4 animals each (overall n=20), except the 
irradiated group where n=8, in order to retain enough 
animals for further analyses.
Raman spectroscopy
Rat brainstems on day 30 were dissected out and 
stored at -80°C in preparation for Raman microspec-
troscopy. Prior to the collection of Raman spectra, 
the brainstems were cut into 20 µm-thick coronal sec-
tions on a cryotome (Leica Microsystems, Germany). 
Sections were mounted on calcium fluoride (CaF2) 
microscope slides. Micro-Raman spectra of all inves-
tigated samples were recorded using a DXR Raman 
Microscope (Thermo Scientific, USA). Samples were 
excited with a 785 nm diode laser at a power density 
of 14 mW. Backscattered Raman emissions were col-
lected through an Olympus microscope with infinity-
corrected confocal optics, a 25-µm pinhole aperture, 
a standard working distance objective 50, a grid of 
1800 lines/mm and a resolution of 2 cm-1. The ac-
quisition time was 60 s with 20 scans. Spectra were 
recorded within the same section of the rat gigantocel-
lular reticular nucleus to minimize the impact of tissue 
inhomogeneity on the Raman readout. The spectral 
range was 600-1800 cm-1. Thermo Scientific OMNIC 
software was used for spectra collection. Cutting out 
of spike artefacts from cosmic rays was performed in 
Spectragryph spectroscopy software ver. 1.2. Raman 
spectra were normalized to the maximum signal 
intensity using Matlab® 2010a package “Raman pro-
cessing” [25]. The background signal was corrected 
using a median filter. The spectrum intensities were 
compared by plotting the mean spectra of groups and 
the mean differences of the spectra between groups. 
Further analysis of Raman spectra included the as-
signation of bands and the assessment of statistical 
significance of their differences. Six animals per ex-
perimental group (overall n=36 animals) were used 
for Raman spectral analysis and five spectra per tissue 
section were recorded.
Immunohistochemistry
The animals that survived up until the 30th day were 
anesthetized with a weight-dependent dose of 10% 
ketamine (Richter pharma AG, Wels, Austria) and 
2% xylazine (Bioveta a.s., Ivanovice na Hane, Czech 
Republic) dissolved as 0.1 mL/100 g b.w. After losing 
the pedal withdrawal reflex (a marker for deep an-
esthesia), the rats were placed in the supine position 
and transcardially perfused with physiological solu-
tion (0.9% NaCl) and 4% paraformaldehyde in 0.1 M 
phosphate buffer, pH 7.4, followed by decapitation 
with a guillotine. 
The brainstems were submerged in 4% para-
formaldehyde for 24 h at 4°C, and then transferred 
to a 30% sucrose solution (in 0.1 M phosphate buf-
fer) until further processing. Before cutting, the 
brains were kept at -80°C for 24 h. Tissue sections 
(30 µm) were cut by a cryostat (Leica, Microsystems, 
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Germany) mounted on microscope slides (Superfrost 
Plus, Thermo Scientific, USA) and stored at 4°C un-
til staining. The sections were washed three times 
with 0.01 M phosphate buffer saline (PBS, pH 7.4). 
To prevent nonspecific binding, the sections were in-
cubated in a blocking solution (10% bovine serum 
albumin (BSA) in PBS with 0.2% Triton X-100) for 1 
h at room temperature (RT). After blocking, the sec-
tions were incubated overnight at 4°C with primary 
antibodies diluted in 2% BSA blocking solution (the 
marker of microglial cells or polyclonal goat anti-
ionized calcium-binding adaptor molecule 1 (Iba-1) 
Abcam, USA 1:250; the marker of astrocytes or poly-
clonal rabbit anti-glial fibrillary acidic protein (GFAP) 
Dako, USA). On the second day, after 5 washes with 
PBS the sections were incubated with appropriate 
fluorophore-conjugated secondary antibodies for 2 h 
at RT (Alexa Fluor 488 donkey-anti goat; Alexa Fluor 
555 donkey-anti rabbit; Invitrogen, USA). After the 
washing steps with PBS, the sections were stained 
with TO-PRO nuclear stain (1:4000, Thermo Fisher, 
USA). The negative control for Iba-1 and GFAP was 
obtained by eliminating the primary antibodies. 
Image acquisition was performed on a confocal laser 
scanning microscope LSM 510 (Zeiss, Germany) in 
multitrack configuration, with the objective lens Plan-
Apochromat 40×  for oil immersion. Confocal imag-
ing was performed with an argon laser (488 nm), two 
helium-neon lasers (543 and 633 nm), and a dichroic 
mirror (488/543/633) with a bandpass filter at 505-530 
and two long pass filters at 585 and 650 nm. Image J 
software was used for analysis of the obtained images. 
The images were converted to 8-bit; the channels were 
split and the auto-threshold was adjusted. The areas 
under antibody reactions were selected to quantify the 
number of pixels (in percentages) per image frame. 
This type of analysis was carried out on three animals 
per group (n=3), two sections per animal. Four images 
were taken per section.
Evaluation of plasma cytokine levels by ELISA
The levels of cytokines (TNF-α, IL-6, and IL-10) 
were measured in the plasma of control and treated 
animals by ELISA (R&D Systems, Minneapolis, USA) 
according to the manufacturer’s instructions. Blood 
samples were taken from the tail vein on the 1st, 7th 
and 28th days. The blood of each animal was collected 
in separate Eppendorf tubes precoated with EDTA 
(10 µL 0.5 M EDTA per 1 mL of blood). Two mL of 
blood were taken from each animal, after which the 
contents were gently mixed and incubated for 30 min 
on ice. After 20 min of centrifugation at 4°C, 2000 
×g, the supernatant (blood plasma) was transferred to 
new Eppendorf tubes and deep-frozen at -80°C until 
the assay. Cytokine concentrations were calculated by 
a referent standard curve constructed using known 
amounts of set-provided recombinant cytokines. Out 
of the 3 planned blood collection time points (ELISA 
days 1, 7 and 28), we successfully completed the first 
two blood collection points (on days 1 and 7) with all 
experimental animal groups. However, on the final 
28th day, there were n=3 for Irr, GLIr-30, GLIr180, 
and GLIr360, while n=4 remained for CTRL and GL.
Statistical analysis
Statistical analysis was performed using SPSS 
Statistics, 18.0 (SPSS Inc., Chicago, USA). The survival 
of animals was tested using Fisher’s nonparametric 
test. The data from Raman microspectroscopy were 
analyzed using the Kruskal-Wallis ANOVA on ranks, 
followed by Dunn’s post hoc test, while the data from 
immunohistochemistry and ELISA were analyzed 
using one-way ANOVA, followed by the LSD and 
Holm-Sidak post hoc test of comparison. The data 
are presented as the mean±standard error of the mean 
(SEM). The difference between groups was considered 
statistically significant for P<0.05.
RESULTS
Survival analysis
Although we previously demonstrated the effect of 
GL2011 on the survival of equally irradiated animals 
[15], we aimed here to confirm these data with a dif-
ferent dosage protocol, albeit on a smaller number 
of animals (pertaining to the 3Rs principle). Out of 
28 experimental animals monitored for survival, 8 
animals died before the final 30th day. In the control 
group of animals (CTRL), as well as in the non-irra-
diated group receiving GL2011 only (GL), the survival 
rate was 100% (n=4/4), while in the group of irra-
diated animals in which GL2011 was omitted (Irr), 
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the survival rate was 37.5% (n=3/8; P<0.05). In the 
remaining three experimental groups where the radio-
protector GL2011 was regularly paired with gamma 
radiation (GLIr-30, GLIr180, and GLIr360), 1 out of 
4 animals in all groups died, hence the survival per-
centage was the same, 75% (n=3/4). All animal deaths 
occurred between the 12th and 16th days post radia-
tion. The survival curve for all experimental groups 
is presented in Supplementary Fig. S2.
Raman spectra analysis
We employed an innovative approach using Raman 
microspectroscopy to define the molecular changes in 
rat brainstem tissue without fixation and without any 
labeling. Thus, in one spectroscopic scan of a micro-
scopically defined tissue area we obtained a composite 
molecular fingerprint for a particular sample.
The average Raman spectrum of control rat brain-
stem tissue (CTRL) is shown in Fig. 1. The assigna-
tion of the most pronounced spectral bands 
was performed as described [26]. Briefly, 
the dominant bands were either from lipid 
compounds (1064, 1304, 1437 cm-1), or from 
the combined contributions of lipids and 
proteins (1128, 1270, 1344 and 1657 cm-1). 
Smaller but defined bands were attributed to 
cholesterol (702 cm-1), phenylalanine (1003 
cm-1), tryptophan (759 and 1619 cm-1) and 
nucleic acids (959, 1373 cm-1).
The spectra of the irradiated tissue dis-
played a fine difference from those of con-
trol tissue. The difference spectra (Fig. 2A) 
revealed a slight increase in the intensity of 
the phenylalanine (1003 cm-1) and a decrease 
in bands assigned to lipid and protein defor-
mation (1344 cm-1, 1657 cm-1), tryptophan 
(759 cm-1) and nucleic acids (959 cm-1). The 
brainstem of rats treated only with GL2011 
did not differ from the control group (not 
shown).
The difference spectra between con-
trol and irradiated tissue after 30 min of 
pre-administration with GL2011 (Fig. 2B) 
pinpoints the decrease in intensity of bands 
attributed to cholesterol, adenine, thymine 
Fig. 1. Average Raman spectra of control rat brainstem tissue with 
the most pronounced bands: Chol – cholesterol (702 cm-1), Trp 
– tryptophan (759, 1619 cm-1), DNA/RNA, symmetric stretching 
vibration of PO4
3- (959 cm-1), Phe – phenylalanine (1003 cm-1), 
skeletal C-C stretch of lipids (1064 cm-1), C-N stretching of pro-
teins and C-C skeletal acyl backbone in lipids (1128 cm-1), amide 
III band in proteins (C-N stretch from α-helix) and C=C groups 
in unsaturated fatty acids and phospholipids (1270 cm-1), CH2 
deformation band in lipid (1304 cm-1), C-H deformation band in 
proteins and lipids (1344 cm-1), T, A, G – ring breathing modes of 
the DNA/RNA bases thymine, adenine, guanine (1373 cm-1), CH2 
deformation band in lipids (1437 cm-1), amide I band of proteins, 
C=C group in lipids (1657 cm-1).
Fig. 2. Difference spectra between control and A – irradiated rat brainstem 
tissue (no protection); B – irradiated tissue with radioprotector administered 
30 min before the irradiation (group GLIr-30); C – irradiated tissue with 
radioprotector administered 3 h after irradiation (group GLIr180); D – ir-
radiated tissue with radioprotector administered 6 h after irradiation (group 
GLIr360). Trp – tryptophan (759 cm-1), DNA/RNA (959 cm-1), Phe – phe-
nylalanine (1003 cm-1), Chol – cholesterol (702 cm-1). Dashed horizontal 
line denote zero difference. Negative values (below the dashed horizontal 
line) denote lower values than the control. Positive values (above the dashed 
horizontal line) denote higher values than the control.
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and tryptophan, while the bands assigned to phe-
nylalanine, lipids and nucleic acids showed a relative 
increase in intensity. Similar changes in the intensi-
ties of bands as in GLIr-30 were observed in GLIr180 
and GLIr360 spectra (Fig. 2C, D, respectively). The 
intensity of the band assigned to phenylalanine (1003 
cm-1) showed a steady increase compared to CTRL in 
all GL2011 experimental groups. The band attributed 
to tryptophan (759 cm-1) diminished in intensity in 
the GLIr-30 group when compared to the CTRL (Fig. 
2B), while it increased in GLIr180 and GLIr360 groups 
(Fig. 2C, D, respectively). The same change in pattern 
was detected in the band at 1657 cm-1 and assigned 
to amide I (not shown), which could suggest an as-
sociation with the level of tryptophan. The intensity of 
bands related to nucleic acids was slightly diminished 
in irradiated tissue, and it rose significantly after treat-
ment with GL2011 either before or after irradiation.
The effect of radiation and radioprotector treat-
ments on the normalized intensities of the bands as-
signed to tryptophan, nucleic acids and phenylalanine, 
ones that exhibited significant spectral differences as 
compared to the control and Irr groups, are shown in 
Fig. 3. There was a significant difference (compared 
to Irr) in the intensity of the tryptophan band at 759 
cm-1 for the GL2011 treatment at 3h (GLIr180) and 6 h 
(GLIr360) after irradiation (Fig. 3A). A gradual increase 
in this band accompanied the delay in radioprotector 
application. For the tryptophan band, the GLIr360 
group also showed a difference compared to the CTRL 
(Fig. 3A). A significant difference was found in the in-
tensity of the nucleic acid band (959 cm-1) between 
the Irr group and each irradiated and radioprotector-
treated group (Fig. 3B), as well as between CTRL and 
GLIr-30 and GLIr360. Here the radioprotector treat-
ment seemed to induce the same effect regardless of 
the timing (Fig. 4B). With regard to the intensity of the 
phenylalanine band (1003 cm-1), there was a significant 
difference (compared to Irr) for radioprotector treat-
ment 30 min prior to irradiation (GLIr-30) and 6 h 
(GLIr360) post-irradiation (Fig. 3C). In addition, the 
increased intensity of the phenylalanine band in each 
irradiated and GL2011-treated group of animals (GLIr-
30, GLIr180 and GLIr360) was significant in compari-
son with the CTRL group (Fig. 3C).
Fig. 3. Mean Raman band intensities with significances as-
signed to tryptophan (A), nucleic acids (B) and phenylalanine 
(C). Statistical analysis was performed using the Kruskal-Wallis 
ANOVA on ranks with Dunn’s post hoc test. Data are presented 
as the mean±SEM), *P<0.05.
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The response of neuroglia
In animals that were irradiated (Fig. 4B), indications 
of Iba-1 positive microglia with scarcely observable 
cellular processes were observed, as well as a slight 
but not significant increase of the percentage of Iba-
1 occupied area when compared to CTRL (Fig. 4A). 
Depending on the timing of GL2011 appli-
cation, microglial cells exhibited different 
changes in morphology. The animals treated 
with the radioprotector 30 min before irra-
diation showed indications of an inflamma-
tory phenotype, which was reflected by the 
continued retraction of microglial process-
es (Fig. 4D). In preparations from animals 
treated with the radioprotector 3 h after irra-
diation (GLIr180), some increase in soma of 
microglial cells could be observed (Fig. 4E), 
while in the GLIr360 group, microglial cells 
displayed a relatively smaller somatic size 
(Fig. 4F). Only the latter GLIr360 treatment 
group showed a significant (P<0.01) change 
in the Iba-1-stained area (Fig. 4G) when 
compared to the Irr group. The radiopro-
tector alone did not produce any outstanding 
changes in microglial morphology (Fig. 4C), 
however, a decrease in Iba-1 staining was ob-
served, but it was not significant (Fig. 4G).
Although assessment of the astrocyte 
marker GFAP (Fig. 4H) did not demonstrate 
any significant differences between groups, 
changes in the astrocyte phenotype due to 
irradiation were noted. More precisely, we 
observed an apparent fragmentation of as-
trocyte processes in the tissue samples of 
irradiated animals (Fig. 4B). A similar ap-
pearance of dystrophic-like astrocytes were 
detected in tissue samples of animals treated 
with the radioprotector 30 min prior to ir-
radiation (Fig. 4D, I). When compared with 
the morphology of astrocytes in the Irr and 
GLIr-30 groups, application of the radiopro-
tector 3 h and 6 h after irradiation led to a 
more compact shape of astrocytes (Fig. 4E, 
F, I). We did not observe a change in the as-
trocyte phenotype in the group of animals 
receiving only the radioprotector treatment 
(GL group, Fig. 4C).
Effect of radiation and GL2011 on plasma 
cytokine levels
Irradiation induced increases in plasma IL-6 levels on 
the 1st and 7th days post-irradiation, with the difference 
Fig. 4. Immunohistochemical staining of the rat brainstem; gigantocellular 
reticular nucleus. Iba-1, microglia marker (green), GFAP, astrocyte marker 
(red) and TO-PRO nuclear stain (blue). A – Control group (CTRL). B – 
Irradiated animals without any protection (Irr). C – Radioprotector only 
group (GL). D – Animals treated with the radioprotector GL2011 30 minutes 
before irradiation (GLIr-30). E – Animals treated with GL2011 180 min after 
irradiation (GLIr180). F – Animals treated with GL2011 360 min after ir-
radiation (GLIr360). Scale bar in images A-F – 40 µm. G, H – Quantitative 
comparison of immunohistochemical staining of brainstem tissue presented 
as the mean±SEM among the six groups CTRL, Irr, GL, GLIr-30, GLIr180 and 
GLIr360. The number of pixels of the Iba – 1 (G) and GFAP (H) staining areas 
expressed as percentages of the image frame area. I – Representative confocal 
images of Irr, GLIr-30, GLIr180 and GLIr360, scale bar 20 µm (arrows indicate 
dystrophic astrocytes in Irr, GLIr-30 and recovered astrocytes in GLIr180 and 
GLIr360). Statistical analysis was performed using one-way ANOVA, followed 
by the LSD post hoc test. Data are presented as the mean±SEM, **P<0.01.
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being statistically significant on the 7th day only (Fig. 
5B). A further significant increase was seen in plasma 
IL-6 levels in the GLIr-30 group as compared to the 
Irr group on the 1st and 28th days after treatment (Fig 
5A, C, respectively). A higher plasma IL-6 level was 
also observed for GLIr180, but it was only significant 
at later time points, on the 7th and 28th days (Fig. 5B, 
C, respectively). Similarly, the GLIr360 group showed 
a significant increase in IL-6 in comparison to the Irr 
group on the 1st and 7th days after treatment (Fig. 5A, 
B, respectively). Surprisingly, on the 28th day, the last 
point in time, analysis of plasma IL-6 levels in the 
GLIr360 group revealed a significantly lower value as 
compared to the CTRL (Fig. 5C). GL2011 alone (GL 
group) also caused an increase in the plasma level of 
IL-6 but achieved significance in comparison to the 
CTRL only on the 7th day after treatment (Fig. 5B). 
Irradiation did not induce a significant increase 
in TNF-α level. However, when compared to the Irr 
group, a significant increase in TNF-α level was de-
tected in all irradiated groups with the radioprotec-
tor on the 1st and 7th days after treatment (Fig. 5D, E, 
respectively). At later time points, this increase was 
significant for the GLIr-30 and GLIr180 groups on the 
28th day (Fig. 5F). The radioprotector alone (the GL 
group) caused an increase in TNF-α level at all time 
points, with a significant difference with respect to 
the CTRL observed on the 1st and 28th days (Fig. 5D, 
F, respectively).
The plasma levels of anti-inflammatory IL-10 
were similar in all experimental groups, with no sig-
nificant differences observed between groups on the 
1st day (Fig. 5G). However, on the 7th day (Fig. 5H), a 
significantly higher level of IL-10 was detected in all 
protected groups as compared to the Irr group, while 
on the 28th day, IL-10 remained significantly higher in 
the GLIr-30 and GLIr180 groups (Fig. 5I). 
DISCUSSION
Radiation exposure can directly or indirectly affect 
the brain by damaging tissue through several mecha-
nisms: the production of reactive oxygen species 
(ROS), oxidative damage and lesions in the DNA mol-
ecule, as well as through mutations that can lead to 
carcinogenesis or cell death [27]. In this study, we fol-
lowed the protective effect of a new natural aminothiol 
radioprotector, GL2011, by following the changes that 
occur in the brainstem at the cellular and molecular 
levels after irradiation/radioprotection. In a previ-
ous study [15], we showed that the administration of 
Fig. 5. Effect of irradiation and treatment with radioprotector GL2011 on plasma cytokine levels. Data presented as mean±SEM 
from rats/CTRL or the treated group. A – IL-6 on the 1st day; B – IL-6 on the 7th day; C – IL-6 on the 28th day; D – TNF-α 
on the 1st day; E – TNF-α on the 7th day; F – T NF-α on the 28th day; G – IL-10 on the 1st day; H – IL-10 on the 7th day; I – 
IL-10 on the 28th day. Statistical analysis was performed using one-way ANOVA, followed by the Holm-Sidak post hoc test. 
*P<0.05, **P<0.01, ***P<0.001 (red asterisks: difference compared to Irr).
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GL2011 at three identical doses at three time points 
resulted in the improvement of the survival rate of 
irradiated rats. In the present study, we confirmed the 
improvement of rat survival, even after application of 
one dose at different times. These findings primar-
ily indicate that GL2011 could elicit radioprotective 
changes in the brain when applied after a radiation 
incident as well as before radiation exposure.
It was shown that murine brains exposed to 10 Gy 
of gamma radiation expressed strong Raman spectral 
changes [28]. In another study performed on male 
Wistar rats, three-model whole-body dosages of gam-
ma rays were used: 14.4 Gy, 9.6 Gy, and 4.8 Gy [29]; 
the lower lethal dose (9.6 Gy) was used to prolong the 
time of observation, delaying the time of death to the 
10th day, while the dose of 4.8 Gy did not cause signifi-
cant changes in the examined marker, melatonin of 
the pineal gland. In the present study, we used 6.7 Gy 
as a mild dose for which Raman microspectroscopy 
did not reveal significant differences from the control 
spectra. However, Raman spectra revealed some inter-
esting molecular signatures for the effects of different 
radioprotector treatments as compared to the control.
In contrast to application prior to radiation (GLIr-
30), an increase in the protein band with a strong lipid 
contribution (1657 cm-1) occurred when the applica-
tion of the radioprotector was delayed, i.e. adminis-
tered post-irradiation (3 h or 6 h), highlighting the 
protective action of GL2011. The increase in intensity 
of this protein band could be explained in part by 
the irradiation-induced activation of transcription 
factors, which in turn control the gene expression of 
proinflammatory cytokines such as TNF-α, IL-1, IL-6, 
and anti-inflammatory cytokines such as IL-4, IL-10, 
IL-13 and TGF-β [30,31]. This is congruent with our 
finding of an increase in the levels of IL-6, TNF-α and 
IL-10 after application of GL2011. 
The increase in intensity of the band at 959 cm-1 
that was observed at all three time points of radio-
protector application revealed an increase in the level 
of nucleic acids. Considering that increased levels 
of proteins were determined in the radioprotected 
groups GLIr180 and GLIr360, this could be related 
to a rise in iRNA as evidenced in the Raman band for 
nucleic acids. These findings on radiation-associated 
molecular damage in rat brainstem parenchyma are in 
agreement with the previously reported radioprotec-
tive enhancement of nucleic acid repair and inhibition 
of cell death [32]. 
The increase in phenylalanine in all groups of 
treated animals could be explained by a change in the 
metabolism of this amino acid. Some proinflamma-
tory cytokines, particularly IL-6 (which is significantly 
increased in the blood plasma of GL2011-treated rats), 
block the conversion of phenylalanine to tyrosine [33], 
hence the increase in the level of the former amino acid.
The level of tryptophan according to Raman spec-
tra followed the trend of nucleic acids and proteins. 
Although there was no significant change in its band 
after radiation, it is known that proinflammatory cy-
tokines, such as IL-6 (which was increased in the Irr 
group on the 7th day) could lead to degradation of 
tryptophan [34,35]. It is of interest to note a compen-
satory rise in the level of tryptophan in GLIr180 and 
GLIr360 groups as compared to irradiated animals.
To follow the cellular response to radiation and 
radioprotection and the underlining neuroinflamma-
tion, tissue sections were immunostained for microg-
lia and astrocytes. Microglial cells are the main cellular 
component involved in the innate immune defense 
of the central nervous system [36]. Reactivation of 
microglial cells is characterized by their acquisition of 
an amoeboid shape in many pathological states, and 
the reduction in the number of processes is one of the 
defining characteristics of activated microglia [37]. 
However, the irradiation protocol used in our study 
showed that 30 days after irradiation, microglial cells 
in the brainstem underwent only a modest change in 
morphology, characterized by scarce cell processes, 
with no significant change in the percentage of the 
area occupied by the Iba-1 signal. Nevertheless, the 
radioprotector itself caused some suppression of the 
microglial marker (that can also be shared with mac-
rophages), an effect that also occurred significantly if 
GL2011 was applied 6 h after irradiation, indicating 
a general inhibitory effect of the radioprotector on 
microglial proliferation. However, the administration 
of only GL2011 (GL group) had no apparent effect 
on microglial morphology, underlining the minimal 
invasiveness of the radioprotector towards glial cells.
Astrocytes are widely distributed in the brain, 
with numerous functions including structural support 
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in the CNS, maintenance of hemodynamics as well as 
secretion of a variety of cytokines [38,39]. Astrocytes 
also support neuronal survival by protecting them 
from oxidative injury. This protective role arises from 
their relatively high content of antioxidants [40], and 
to inhibit inflammatory processes in the brain, they 
also produce soluble factors that inhibit microglial 
activation, such as the TGF-β and prostaglandins 
[41,42]. Studies have reported that doses above LD50, 
typically greater than 10 Gy, increase the presence of 
GFAP-positive astrocytes, while lower doses, typi-
cally below 8 Gy, did not induce noticeable changes 
in GFAP, even 30 days after irradiation [43,44], which 
is in agreement with our quantitative data. Regarding 
the morphology of astrocytes, irradiation induced 
fragmentation and a dystrophic-like phenotype that 
remained after application of the radioprotector 30 
min before irradiation, and was reminiscent of astro-
cyte damage but also of astrogliosis, which is consid-
ered to be a common response to general CNS damage 
[45]. Conversely, we observed that application of the 
radioprotector 3 h or 6 h after irradiation promoted a 
recovery of the astrocytic phenotype, suggesting that 
the application of GL2011 was more beneficial for as-
troglia if applied post-irradiation.
The brain and the immune system are in bidi-
rectional communication, which is essential for 
maintaining homeostasis [46]. The brain modulates 
immune functions through autonomic and neuro-
endocrine pathways [47]. Neurotransmitters and 
hormones released by these neural pathways inter-
act with immune cells to alter global immune func-
tions, including cytokine production [48]. Radiation 
is known to activate cytokine complexes that function 
in a highly orchestrated way, enabling interactions 
between mesenchymal, epithelial and immune cells 
[49]. Proinflammatory cytokines are rapidly activated 
after tissue irradiation, subsequently generating free 
radicals, including ROS and reactive nitrogen species. 
This proinflammatory phase is sustained long after 
radiation exposure. The balance between pro- and 
anti-inflammatory responses can oscillate back and 
forth for a long time after irradiation, and is consid-
ered critical in determining a positive or a negative 
outcome [50].
Elevated levels of TNF-α have been found after 
irradiation of different human or mammalian cells, 
such as alveolar macrophages or tumor cells, while the 
overproduction of IL-6 and IL-8 has been described 
in keratinocytes, fibroblasts and glioma cells after 
both X-ray or UV exposure [51]. Our results show a 
sustained increase in plasma proinflammatory cyto-
kines, IL-6 in almost all the groups that were irradi-
ated and received GL2011 under different application 
regimes, likewise TNF-α, but with a more persistent 
effect throughout the protected groups. Notably, the 
non-irradiated GL group (radioprotector only) gener-
ally also showed an increase in IL-6 and TNF-α at all 
times. AS101 (ammonium trichloro(dioxoethylene-
O-O')tellurate), a member of another class of radio-
protectors and immunomodulators, was found to 
stimulate the production of IL-1, IL-6 and TNF-α, 
which underlines its role [52]. Thus, in addition to 
the previously published aminothiol mechanisms 
of radioprotection [11,15,16], here we showed with 
GL2011 another function, related to the manipulation 
of cytokine pathways.
In our experiments, the Irr group exhibited a rise 
in IL-6 on the 1st day and a significantly higher level 
on the 7th day, which is similar to the findings that 
elevated IL-6 production increases with the dose of 
radiation, reaching a maximum effect later after ir-
radiation [53]. On the other hand, IL-6 induces radia-
tion resistance [54], and by acting as a multifunctional 
cytokine, it regulates the immune response, the acute 
phase response and inflammatory reactions and he-
matopoiesis [55]. In addition, it was observed that 
some cytokines (TNF-α and IL-6, among others) were 
highly represented in the conditioned medium of an 
irradiated glioblastoma cell line [56]. The significant 
rise in IL-6 and TNF-α levels concomitantly with IL-
10 was noted in the GLIr180 group as compared to the 
Irr group, as well as in the GLIr-30 group. However, 
when measured on the final 28th day, the treatment 
with GL2011 6 h after radiation ceased to show an 
effect (as compared to Irr) for all inflammatory mark-
ers. On the 1st day after treatment, only the proinflam-
matory cytokines were activated, and on the 7th day 
this was counterbalanced by a rise in anti-inflamma-
tory IL-10, which may indicate a healing effect with 
GL2011 at all treatment times. It is also worth noting 
that IL-6 can act in concert with IL-10 at the transla-
tional level, inhibiting TNF-α protein expression by 
astrocytes [57], which suggests that these humoral 
factors act as important regulators of other cytokines 
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whose actions could be detrimental to the brain. 
However, the rise in the level of a specific cytokine in 
a disease setting or following radiation does not neces-
sarily indicate how cohorts of cytokines interact with 
one another or whether a specific cytokine is causally 
involved in inflammatory tissue damage [49].
The results of our study confirmed the increased 
survival of animals treated with GL2011 either before 
or after irradiation. On the molecular level, Raman 
microspectroscopy revealed that the radioprotector 
mostly stimulated the turnover of nucleic acids, while 
immunohistochemistry showed diminished infiltra-
tion of microglial cells, especially if GL2011 was ap-
plied after irradiation. A possible radioprotective ef-
fect was also indicated by the change in the pattern of 
cytokines release. These data suggest that the radio-
protector GL2011, operating as an immune system 
modulator, protects the brainstem from the effect of 
whole-body radiation. 
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